The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar

• Status: Completed
• Trial end date: 2019-04-09
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to:

1. Determine the prevalence of Helicobacter infection in Myanmar (this would be the largest ever series in the country)

2. Determine the clinical and epidemiological associations of Helicobacter infection in Myanmar

3. Determine the utility of stool antigen testing to diagnose the infection and confirm eradication

4. Compare the relative efficacies of concomitant and sequential therapy

5. Determine the relative efficacies of first, second and third line therapies in Myanmar in 2018

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kirby Institute
• Collaborator: University of Medicine 2, Yangon, Myanmar
• Treatments: Amoxicillin; Clarithromycin; Rabeprazole; Tinidazole

Criteria

Inclusion Criteria:

• Satisfies one of the criteria for H. pylori testing in the 2017 American College of Gastroenterology guidelines

• Informed consent

Exclusion Criteria:

• No informed consent